AstraZeneca has selected a novel chronic kidney disease (CKD) target to advance to its drug development portfolio, under its collaboration with fellow UK-based artificial intelligence (AI) company BenevolentAI. 28 January 2021
Novartis’ Steven Baert, chief people and organization officer, and Elizabeth Theophille, chief technology transformation officer, provide an Expert View predicting what will dictate developments in the pharmaceutical and healthcare industries in 2021. 19 January 2021
Research from industry analyst GlobalData has found that established players in Japan’s immunology market have a dominant lead in the digital marketing space. 15 December 2020
The European pharmaceutical industry has thrown its weight behind the use of artificial intelligence (AI) in drug development, with the publication of a new paper advocating its use. 3 December 2020
British artificial intelligence specialist InstaDeep and German biotech firm BioNTech have deepened ties, embarking on a multi-year project to develop new technologies. 25 November 2020
insitro, a California-based machine-learning driven drug discovery and development company, has entered into a five-year, discovery collaboration with US pharma major Bristol Myers Squibb focused on the discovery and development of novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). 29 October 2020
An Expert View from Karen Noonan at the Association of Clinical Research Organizations (ACRO) on adopting a more flexible approach to trials moving forward, something made all the more important by the COVID-19 pandemic. 28 September 2020
At the annual congress of the European Society of Medical Oncology (ESMO), taking place virtually, Johnson & Johnson’s pharma arm Janssen hopes to raise the bar with quality of life data for Erleada (apalutamide). 17 September 2020
US tech-based therapy firm Click Therapeutics has notched up another big pharma partner, as its joins with Germany’s Boehringer Ingelheim for the development and commercialization of a prescription-based digital therapeutic. 11 September 2020
Germany’s Bayer and USA-based Recursion Pharmaceuticals, a digital biology company industrializing drug discovery, have entered into a strategic collaboration. 9 September 2020
Pierre-Georges Roy, partner at M&A advisor Results International, provides an Expert View on why deals kept being made even as much of society shut down. 18 August 2020
Developments in artificial intelligence (AI) and machine learning (ML) are playing an increasingly influential role in the biotech space, driving the formation of new partnerships ,between the tech and healthcare industries. 3 August 2020
Artificial intelligence specialist Healx has launched a partnership with Muscular Dystrophy UK (MDUK) to find novel therapies for facioscapulohumeral muscular dystrophy (FSHD). 15 July 2020
Akili, a funded entity of London-listed biotech firm PureTech Health, today announced that it has received a Conformité Européenne (CE) Mark for EndeavorRx (AKL-T01) as a prescription-only digital therapeutic software intended for the treatment of attention and inhibitory control deficits in pediatric patients with attention deficit hyperactivity disorder (ADHD). 23 June 2020
London-listed biotech firm PureTech Health’s founded entity, Akili Interactive, has gained US Food and Drug Administration clearance for EndeavorRx (AKL-T01) as a prescription treatment for children with attention-deficit/hyperactivity disorder (ADHD). 16 June 2020
The new US President has repealed an executive order from October 2023, signed by the Biden administration, that sought to establish rigorous safeguards for artificial intelligence (AI) development. 22 January 2025
French pharmaceutical company Servier and Google Cloud have announced an expanded five-year partnership aimed at leveraging artificial intelligence (AI) and generative AI to accelerate drug research and development. 16 January 2025
A collection of some of the largest US health systems, in collaboration with the Regeneron Genetics Center, have announced the launch of the Truveta Genome Project. 16 January 2025
Privately-held Italian drugmaker Menarini and its oncology-focused subsidiary Stemline Therapeutics have entered into a licensing deal with AI-driven biotech Insilico Medicines. 15 January 2025
Dyno Therapeutics, a privately-held US genetic technologies company applying AI to enable in vivo gene delivery, has announced that Roche has exercised its option to license a novel capsid for use in a gene therapy program for an undisclosed neurological disease indication. 13 January 2025
Belgian biopharmaceutical company UCB has entered into a license agreement with Ailux Biologics, the biologics discovery division of XtalPi, to leverage its AI platform. 9 January 2025
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 20 December 2024
Shanghai-based Fangzhou, has entered into a strategic partnership with the Chinese business of Bristol Myers Squibb China, with the goal of enhancing digital platforms for chronic disease management. 19 December 2024
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
The pharmacovigilance (PV) teams within the pharmaceutical industry currently report allocating 40 to 85% of budgets towards case processing. With case processing volumes growing at a rate of 10 to 15% annually, life sciences organizations are aiming to reduce costs and automate time-consuming processes while maintaining or improving quality. 9 December 2024
Boston-based AI Proteins, a biotech that uses computational de novo protein design to create therapeutic miniproteins, has entered a research collaboration and option agreement with US pharma major Bristol Myers Squibb. 4 December 2024
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Digital therapeutics company GAIA has announced the signing of a licensing agreement for attexis with fellow German firm MEDICE Arzneimittel Pütter. 14 November 2024